A new experimental pain medicine may offer strong relief after surgery without using opioids.
In a clinical trial involving adults recovering from tummy tuck surgery, the drug LTG-001 reduced moderate-to-severe pain more than an inactive placebo.
The higher dose also produced encouraging results compared with a commonly used opioid treatment, although the study was not designed to prove that one drug was better than the other.
The trial was led by Latigo Biotherapeutics and the findings were published in the New England Journal of Medicine. LTG-001 is an oral medicine that targets a part of the nervous system involved in carrying pain signals. Researchers hope this approach could eventually provide another option for patients who need powerful short-term pain relief.
Opioids such as hydrocodone can be extremely effective after surgery or serious injury. They reduce pain by attaching to opioid receptors in the brain and other parts of the body. But the same system can also produce dependence, addiction, dangerous breathing problems and overdose.
Even when opioids are taken as prescribed, they can cause unpleasant effects such as nausea, vomiting, sleepiness and constipation. Doctors therefore have a difficult balance to manage after major surgery. Patients need enough pain relief to recover and move comfortably, but unnecessary opioid exposure is best avoided.
LTG-001 takes a very different route. It blocks Nav1.8, a sodium channel found mainly in nerve cells that detect painful events in the body. These nerve cells send electrical messages toward the spinal cord and brain, where the signals are experienced as pain.
Because Nav1.8 is concentrated in pain-sensing nerves outside the brain, scientists believe blocking it may reduce pain without producing the rewarding effects that make opioids addictive. Interest in this target has grown rapidly in recent years. In 2025, suzetrigine became the first medicine in this newer class to receive approval for acute pain.
However, developing a powerful Nav1.8 medicine has not been easy. Earlier drugs have produced mixed results, and some have provided only modest relief. LTG-001 was designed to strongly block Nav1.8 and reach the peripheral nerves where pain signals begin.
The new Phase IIb trial included 343 adults between ages 18 and 65. All had undergone lower abdominal abdominoplasty, commonly called a tummy tuck, and reported a pain level of at least 5 on a 10-point scale within four hours after surgery. The patients were randomly placed into four treatment groups.
One group received a lower dose of LTG-001, beginning with 300 milligrams and then receiving 150 milligrams every 12 hours. Another received a higher dose, starting with 450 milligrams followed by 300 milligrams every 12 hours. Treatment continued for 48 hours.
A third group received hydrocodone combined with acetaminophen every six hours, while a fourth received placebo. Neither the participants nor the investigators knew which assigned treatment patients were receiving during the blinded trial. This design helps reduce expectations and other biases that can influence reported pain.
Both doses of LTG-001 produced significantly better overall pain relief than placebo during the 48-hour treatment period. Pain relief also began fairly quickly, with meaningful improvement reported within about an hour. More than half of patients receiving the higher dose completed the study period without needing backup opioid medicine, compared with about 22% of patients receiving placebo.
The high-dose LTG-001 group also had greater average pain relief over 48 hours than the hydrocodone-acetaminophen group. That result is encouraging, but it needs careful interpretation. The trial was not designed or statistically set up to establish that LTG-001 is superior or equivalent to the opioid treatment.
The study therefore represents promising mid-stage evidence rather than proof that LTG-001 can replace opioids. It tested one type of surgery, followed patients for only 48 hours and involved a few hundred adults. Larger Phase III trials will be needed to confirm effectiveness, identify less common side effects and determine how the drug performs in other painful conditions.
Still, the results support the idea that strong pain relief may be possible without acting on opioid receptors. If later trials confirm the findings, LTG-001 could help doctors reduce opioid use after some operations while still treating pain effectively.
Its real value will depend on whether the benefits remain strong in larger studies and whether long-term safety, dosing and practical use compare favorably with existing medicines.
If you care about health, please read studies that vegetarian women have higher risk of hip fracture, and these vitamins could help reduce bone fracture risk.
For more health information, please see recent studies that Krill oil could improve muscle health in older people, and Jarlsberg cheese could help prevent bone thinning disease.
Source: Latigo Biotherapeutics.
